Urology

Latest Ask the Experts

Biomarker Assays for Prostate Cancer Management

Should biomarker assays be an integral part of prostate cancer patient care?

Urology News

Latest Urology News

Benign Prostatic Hyperplasia (BPH) Desmopressin Effectively Treats Nocturia in BPH

Desmopressin Effectively Treats Nocturia in BPH

Nocturia improved 43% in patients receiving oral desmopressin alone and 64.3% in those receiving desmopressin and an alpha-blocker.

Overactive Bladder (OAB) Overactive Bladder Treatment: Which Is the Most Cost-Effective Option?

Overactive Bladder Treatment: Which Is the Most Cost-Effective Option?

Study authors developed a Markov model with health states based on daily urinary incontinence episodes (UIEs) to compare the cost-effectiveness of onabotulinumtoxinA, implantable sacral nerve stimulation devices, percutaneous tibial nerve stimulation, anticholinergic medications, and mirabegron versus BSC for the management of refractory OAB.

Urology Ultrarestrictive Opioid Rx Protocol Cuts Postoperative Opioid Use

Ultrarestrictive Opioid Rx Protocol Cuts Postoperative Opioid Use

UROPP reduces opioids prescribed after gynecologic, abdominal surgery without negative effects.

Hypogonadism Hypogonadism Predicts Varicocele Repair

Hypogonadism Predicts Varicocele Repair

Hypogonadism and serum testosterone evaluation nearly doubled the odds a man would undergo varicocelectomy.

Prostate Cancer Prostate Cancer Linked to Inflammatory Bowel Disease

Prostate Cancer Linked to Inflammatory Bowel Disease

IBD is associated with a nearly 5-fold increased risk of prostate cancer, study finds.

Bladder Cancer Neoadjuvant Chemotherapy for MIBC Ups Disease-Free Survival

Neoadjuvant Chemotherapy for MIBC Ups Disease-Free Survival

Patients with muscle-invasive bladder cancer had a 22% decreased risk of disease progression if they received neoadjuvant rather than adjuvant chemotherapy, a study found.

Hypogonadism Testosterone Measurements, TRT Prescribing Infrequent in PCa Care

Testosterone Measurements, TRT Prescribing Infrequent in PCa Care

More than half of UK specialists surveyed said measuring testosterone levels in patients with nonmetastatic prostate cancer was not their routine practice.

Urology ASH: Rivaroxaban Prevents Blood Clots in At-Risk Cancer Patients

ASH: Rivaroxaban Prevents Blood Clots in At-Risk Cancer Patients

Risk for patients in rivaroxaban group reduced during the on-treatment period

Hypogonadism Study: Testosterone Replacement Does Not Increase DVT Risk

Study: Testosterone Replacement Does Not Increase DVT Risk

In a study, the rate of deep vein thrombosis in treated hypogonadal men was just 0.8% over 2 years of follow-up.

Bladder Cancer Noninvasive Diagnostic Imaging Accurately IDs Bladder Cancer

Noninvasive Diagnostic Imaging Accurately IDs Bladder Cancer

Method evaluating cells collected from urine shows 94% diagnostic accuracy.

Kidney Cancer Lymphadenectomy Offers No Survival Benefit in Nonmetastatic RCC

Lymphadenectomy Offers No Survival Benefit in Nonmetastatic RCC

Lymph node dissection did not influence overall survival even among patients with clinically positive nodal disease.

Hypogonadism Xyosted Now Available for Treatment of Testosterone Deficiency

Xyosted Now Available for Treatment of Testosterone Deficiency

Prior to starting Xyosted, the patient's baseline cardiovascular risk should be considered and blood pressure should be adequately controlled.

Prostate Cancer ADT May Be Less Beneficial for Gleason 9 to 10 Prostate Cancer

ADT May Be Less Beneficial for Gleason 9 to 10 Prostate Cancer

Men with Gleason score 9 to 10 prostate cancer derive no significant survival benefit from androgen deprivation therapy.

Prostate Cancer Ultrasound + MRI Improves High-Grade Prostate Cancer Detection

Ultrasound + MRI Improves High-Grade Prostate Cancer Detection

Well demarcated hypoechoic areas in suspicious regions on MRI identify men more likely to have Gleason 7 or higher prostate cancer found on biopsy.

Bladder Cancer Post-Cystectomy Readmission Predictors Identified

Post-Cystectomy Readmission Predictors Identified

Overweight and obesity, diabetes, and postoperative complications increase the likelihood of being readmitted within 30 days of hospital discharge among radical cystectomy patients.

Prostate Cancer Prostate Cancer Risk Lower in Long-Term Users of Lipid-Lowering Drugs

Prostate Cancer Risk Lower in Long-Term Users of Lipid-Lowering Drugs

In a study, taking lipid-lowering drugs for 10 or more years was associated with a 32% lower risk prostate cancer.

Urology FDA Approves Vitrakvi for Cancers With Certain Genetic Trait

FDA Approves Vitrakvi for Cancers With Certain Genetic Trait

Drug targets solid tumors with NTRK gene fusion without a known acquired resistance mutation

Prostate Cancer Delayed Prostate Cancer Treatment May Up Relapse Risk

Delayed Prostate Cancer Treatment May Up Relapse Risk

Patients whose radical prostatectomy was delayed more than 6 months had a nearly 2-fold increased risk of biochemical recurrence, a study found.

Urology Patient Education Ups VTE Prophylaxis in Hospital Setting

Patient Education Ups VTE Prophylaxis in Hospital Setting

Targeted patient-centered intervention reduces nonadministration of pharmacologic prophylaxis.

Prostate Cancer Very High-Risk Prostate Cancer Criteria Validated as a Risk Stratum

Very High-Risk Prostate Cancer Criteria Validated as a Risk Stratum

Men with very high-risk (VHR) PCa are more likely to have adverse pathologic features and outcomes after radical prostatectomy than those with high-risk but not VHR PCa.